Abstract
Objective
The aim of this study was to determine the economic burden from a societal perspective and the health-related quality of life (HRQOL) of patients with haemophilia in Europe.
Methods
We conducted a cross-sectional study of patients with haemophilia from Bulgaria, France, Germany, Hungary, Italy, Spain Sweden and the UK. Data on demographic characteristics, health resource utilisation, informal care, loss of labour productivity and HRQOL were collected from the questionnaires completed by patients or their caregivers. HRQOL was measured with the EuroQol 5-domain (EQ-5D) questionnaire. The costs have been estimated from a societal perspective adopting a bottom-up approach.
Results
A total of 401 questionnaires were included in the study, of which 339 were collected from patients with haemophilia and 62 from caregivers. The lowest average annual cost per person was reported in Bulgaria (€6,660) and the highest in Germany (€194,490). Our results demonstrate both a large difference from country to country in the average annual cost per patient in 2012 and the driving role of drugs in costs. Drugs represent nearly 90 % of direct healthcare costs in a majority of the countries analysed (Hungary, Italy, Spain and Germany). In Bulgaria, France and Sweden, however, healthcare services (visits, tests and hospitalisations) prevail. Costs are also shown to differ between children and adults. The mean EQ-5D index score for adult patients was 0.69 and mean EQ-5D VAS was 66.6. The mean EQ-5D index score for carers was 0.87 and mean EQ-5D VAS was 75.5. In the disability score, 60 % showed no disability and measuring caregiver burden with the Zarit Index produced an overall mean score of 25.3.
Conclusion
We have shown that haemophilia is associated with a substantial economic burden and impaired HRQOL. Studies on cost of illness and HRQOL are important for haemophilia as the future of this disease is likely to change with the development of new innovative treatments. The introduction of these treatments will most likely impact future costs related to haemophilia.
Similar content being viewed by others
References
Rosendal, F.R., Briet, E.: The increasing prevalence of haemophilia. Thromb. Haemostasis 63, 145 (1990)
World Federation of Hemophilia (2012) Report on the Annual Global Survey 2012, December http://www1.wfh.org/publications/files/pdf-1574.pdf. Accessed 17 Aug 2015
Evatt, B.L.: Demographics of haemophilia in developing countries. Semin. Thromb. Hemostasis 31, 489–494 (2005)
Stonebraker, J.S., Bolton-Maggs, P.H.B., Soucie, M.J., et al.: A study of variations in the reported haemophilia A prevalence around the world. Haemophilia 16, 20–32 (2010)
DeJager, T., Pericleous, L., KoKot-Kierapa, M., et al.: Burden and management of factor XIII deficiency. Haemophilia 20, 733–740 (2014)
Sherry, D.D.: Avoiding the impact of muscolo-skeletal pain on quality of life in children with haemophilia. Orthop. Nurse 27, 103–108 (2008)
Antunes, S.V., Vicari, P., Cavalheiro, S., Bordin, J.O.: Intracranial haemorrhage among a population of haemophilic patients in Brazil. Haemophilia 9, 573–577 (2003)
Siddiqi, A.E., Ebrahim, S.H., Soucie, J.M., Parker, C.S., Atrash, H.K.: Burden of disease resulting from hemophilia in the U.S. Am. J. Prev. Med. 38(4 Suppl), S482–S488 (2010)
Nilsson, I.M., Berntorp, E., Löfqvist, T., Pettersson, H.: Twenty-five years’ experience of prophylactic treatment in severe haemophilia A and B. J. Intern. Med. 232, 25–32 (1992)
Berntorp, E., Boulyjenkov, V., Brettler, D., et al.: Modern treatment of haemophilia. Bull. World Health Organ. 73, 691–701 (1995)
National Hemophilia foundation (2007) MASAC (Medical and Scientific Advisory Council) Recommendation 179: MASAC recommendation concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding). https://www.hemophilia.org/sites/default/files/document/files/masac179.pdf Accessed 23 Dec 2014
Manco-Johnson, M.J., Abshire, T.C., Shapiro, A.D., et al.: Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N. Engl. J. Med. 357, 535–544 (2007)
Santagostino, E., Lents, S.R., Busk, A.K., Regnault, A., Iorio, A.: Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: insights from two clinical trials on turoctocog alfa. Haemophilia 20, 527–534 (2014)
Makris, M.: Prophylaxis in haemophilia should be life-long. Blood Transfus. 10, 165–168 (2012)
van Dijk, K., Fischer, K., van der Born, J.G., Scheibel, E., Ingersley, J., van den Berg, H.M.: Can long-term prophylaxis for severe haemophilia be stopped in adulthood? Results from Denmark and the Netherlands. Br. J. Haematol. 130, 107–112 (2005)
Valentino, L.A., Mamonov, V., Hellmann, A., Prophylaxis Study Group, et al.: A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J. Thromb. Haemost. 10, 359–367 (2012)
von Mackensen, S., Gringeri, A., Siboni, S.M., et al.: Health-related quality of life and psychological well-being in elderly patients with haemophilia. Haemophilia 18, 345–352 (2012)
Tagliaferri, A., Rivolta, G.F., Iorio, A., et al.: Mortality and causes of death in Italian persons with haemophilia, 1990–2007. Haemophilia 16, 437–446 (2010)
Johnson, K., Zhou, Z.Y.: Costs of care in hemophilia and possible implications of health care reform. Hematology 1, 413–418 (2011)
Miners, A.H., Sabin, C.A., Tolley, K.H., et al.: Cost-utility analysis of primary prophylaxis versus treatment on-demand for individuals with severe haemophilia. Pharmacoeconomics 20, 759–774 (2002)
Miners, A.H.: Economic evaluations of prophylaxis with clotting factor for people with severe haemophilia: why do the results vary so much? Haemophilia 19, 174–180 (2013)
Carlsson, S.K., Höjgård, S., Glomstein, A., et al.: On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome. Haemophilia 9, 555–566 (2003)
Brown, S.A., Aledort, L.M.: The Round Table Group: economic challenges in haemophilia. Haemophilia 10(Suppl. 1), 44–49 (2004)
Gringeri, A., Lundin, B., von Mackensen, S., Mantovani, L., Mannucci, P.M., ESPRIT Study Group: A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J. Thromb. Haemost. 9, 700–710 (2011)
Lindvall, K., von Mackensen, S., Berntorp, E.: Quality of life in adult patients with haemophilia—a single centre experience from Sweden. Haemophilia 18, 527–531 (2012)
Carvalhosa, M., Henrard, S., Lambert, C., Hermans, C.: Physical and mental quality of life in adult patients with haemophilia in Belgium: the impact of financial issues. Haemophilia 20, 479–485 (2014)
Royal, S., Schramm, W., Berntorp, E., Giangrande, P., Gringeri, A., Ludlam, C., Kroner, B., Szucs, T., European haemophilia economics study group: Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients. Haemophilia 8, 44–50 (2002)
Fischer, K., van der Bom, J.G., Molho, P.: Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome. Haemophilia 8, 745–752 (2002)
Klamroth, R., Pollmann, H., Hermans, C.: The relative burden of haemophilia A and the impact of target joint develop on health related quality of life: results from the ADVATE post-authorisation safety surveillance (PASS) study. Haemophilia 17, 412–421 (2011)
Henrard, S., Devleesschauwer, B., Beutels, P., Callens, M.: The health and economic burden of haemophilia in Belgium: a rare, expensive and challenging disease. Orphanet J Rare Dis 9, 39 (2014)
Nerich, V., Tissot, E., Faradji, A.: Cost-of-illness study of severe haemophilia A and B in five French haemophilia treatment centres. Pharm. World Sci. 30, 287–292 (2008)
Auerswald, G., Von Depka Prondzinski, M., Ehlken, B.: Treatment patterns and cost-of-illness of severe haemophilia in patients with inhibitors in Germany. Haemophilia 10, 499–508 (2004)
Gringeri, A., Mantovani, L.G., Scalone, L.: Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 102, 2358–2363 (2003)
Brooks, R.: EuroQol: the current state of play. Health Policy 37, 53–72 (1996)
Drummond, M.F., O’Brien, B., Stoddart, G.L., Torrance, G.W.: Methods for the economic evaluation of health care programmes, 2nd edn. Oxford University Press, Oxford (1997)
McDaid, D.: Estimating the costs of informal care for people with Alzheimer’s disease: methodological and practical challenges. Int. J. Geriatr. Psychiatry 16, 400–520 (2001)
van den Berg, B., Brouwer, W., Koopmanschap, M.: Economic valuation of informal care: an overview of methods and applications. Eur. J. Health Econ. 5, 36–45 (2004)
Hodgson, T.A., Meiners, M.R.: Cost-of-illness methodology: a guide to assessment practices and procedures. Milbank Mem. Fund Q. 60, 429–491 (1982)
Dolan, P.: Modeling valuations for EuroQol health states. Med. Care 735, 1095–1108 (1997)
Szende, A., Janssen, B., Cabases, J. (eds.): Self-reported population health: an international perspective based on EQ-5D. Springer, Netherlands (2014)
Mahoney, F.I., Barthel, D.W.: Functional evaluation: the Barthel index. Md. State Med. 14, 61–65 (1965)
Shah, S., Vanclay, F., Cooper, B.: Improving the sensitivity of the Barthel index for stroke rehabilitation. J. Clin. Epidemiol. 42, 703–709 (1989)
Hérbert, R., Bravo, G., Préville, M.: Reliability, validity, and reference values of the Zarit Burden Interview for assessing informal caregivers of community-dwelling older persons with dementia. Can. J. Aging 19, 494–507 (2000)
O’Mahony, B., Noone, D., Giangrande, P.L.F., Prihodova, L.: Haemophilia care in Europe—a survey of 35 countries. Haemophilia 2013(19), e239–e247 (2013)
O’Mahony, B., Noone, D., Giangrande, P.L.F., Prihodova, L.: Haemophilia care in Europe: a survey of 19 countries. Haemophilia 17, 35–40 (2011)
Pocoski, J., Benjamin, K., Michaels, L.A., Flood, E., Sasane, R.: An overview of current trends and gaps in patient-reported outcome measures used in haemophilia. Eur. J. Haematol. 93 Suppl 75, 1–8 (2014)
Tarricone, R.: Cost-of-illness analysis: what room in health economics? Health Policy 77, 51–63 (2006)
Drummond, M., Sculpher, M.J., Torrance, G.W., et al.: Methods for economic evaluation of health care programmes, 3rd edn. Oxford University Press, Oxford (2005)
Berntorp, E., Shapiro, A.D.: Modern haemophilia care. Lancet 379, 1447–1456 (2012)
Taruscio, D., Gentile, A.E., Evangelista, T., Frazzica, R.G., Bushby, K.: Centres of Expertise and European Reference Networks: key issues in the field of rare diseases. The EUCERD recommendations. Blood Transfus. Suppl 3, 621–625 (2014)
Acknowledgments
The authors wish to thank: National Alliance of People with Rare Diseases (NAPRD), Bulgaria; Alliance Maladies Rares, France; ACHSE, Germany; Hungarian Federation of People with Rare and Congenital Diseases (RIROSZ), Hungary; Federazione Italiana Malattie Rare (UNIAMO), Italy; the Consulta Nazionale delle Malattie Rare, Italy; Rare Diseases Sweden; Federación Española de Efermedades Raras (FEDER), Spain; Rare Disease UK and Rare Diseases Europe (EURORDIS); Bulgarian Haemophilia Society; Association française des hémophiles, France; Interessengemeinschaft Hämophiler e.V., Germany; Magyar Hemofília Egyesület, Hungary; FEDEMO—Federazione delle Associazioni Emofilici ONLUS and A.E.L.—Associazione emofilici del Lazio, Italy; Swedish Hemophilia Society, Sweden; Asociación Andaluza de Hemofilia Canf Cocemfe and Asociaciónde Hemofilia de la Comunidad de Madrid, Spain; Haemophilia Society, UK.
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Funding
Supported by the Social/Economic Burden and Health-Related Quality of Life in Patients with Rare Diseases in Europe Project, which received funding from the European Union within the framework of the Health Programme (grant A101205). The Executive Agency of the European Union is not responsible for any use that may be made of the information contained herein.
Conflict of interest
The authors declare that they have no conflicts of interest.
Additional information
Members of the BURQOL-RD Research Network listed in the Supplementary Annex 1.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Cavazza, M., Kodra, Y., Armeni, P. et al. Social/economic costs and quality of life in patients with haemophilia in Europe. Eur J Health Econ 17 (Suppl 1), 53–65 (2016). https://doi.org/10.1007/s10198-016-0785-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10198-016-0785-2